EpiPen Competitor Auvi-Q Re-Enters Market in February

Jan 20, 2017

CNBC

Virgina-based Kaleo Pharma will re-introduce its competitor to Mylan's EpiPen back to the market on February 14.

The list price for Kaleo's Auvi-Q is $4,500, but the drugmaker guarantees a cash price of no more than $360 for two auto-injectors.

Kaleo has said many insurers will cover the product. Additionally, the drugmaker will offer a program called "Auvi-Q AffordAbility" that guarantees U.S. patients with commercial insurance will have no out-of-pocket costs for the devices, plus free product for those who don't have insurance and have a household income of less than $100,000.

The Auvi-Q auto-injector was pulled from the market in 2015 when it was recalled in for inaccurate dosage delivery.

Read the CNBC coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments